Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03989947 · ClinicalTrials.gov registry record · Phase 2
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
A Phase 2 study of Achondroplasia, sponsored by BioMarin Pharmaceutical.
- Active
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 16
- Study locations
NCT03989947 is a Phase 2 study of Achondroplasia that is active but no longer recruiting, run by BioMarin Pharmaceutical. The registered enrollment target is 73 participants, below the 143-participant average among 9 other Achondroplasia trials with a reported enrollment target (49% lower). The trial reports 16 study locations across 11 states.
The verdict
NCT03989947, a Phase 2 study of Achondroplasia, is active but no longer recruiting, sponsored by BioMarin Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension study will receive a daily dose of BMN111 by subcutaneous injection according to their age as determined by 111-206.
Conditions Studied
Interventions
- DRUG Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Study Locations (16)
Other
- Osaka University - Osaka
- Saitama Children's Medical Center - Saitama
- Tokushima University Hospital - Tokushima
- Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital - London
- Sheffield Children's NHS Foundation Trust - Sheffield
California
- Children's Hospital & Research Center Oakland - Oakland
- Harbor - UCLA Medical Center - Torrance
Delaware
- Alfred I. duPont Hospital for Children - Wilmington
Georgia
- Emory University - Decatur
Illinois
- Ann Robert and H. Lurie Children's Hospital of Chicago - Chicago
Ohio
- Cincinnati Childrens Hospital - Cincinnati
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2019-06-12 |
| Est. Completion | 2038-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03989947
The ClinicalTrials.gov registry entry for NCT03989947 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 9 other Achondroplasia trials with a reported enrollment target (49% lower). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 1 intervention - of which Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. is the first listed.
NCT03989947 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT03989947 about?
NCT03989947 is a clinical study titled "An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia". This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111 or placebo treatmen...
What is the current status of trial NCT03989947?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2019-06-12. Estimated completion is 2038-05.
What conditions does trial NCT03989947 study?
This clinical trial studies the following conditions: Achondroplasia.
What interventions are being tested in trial NCT03989947?
The interventions under investigation include: Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. (DRUG).
Who is sponsoring clinical trial NCT03989947?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03989947 being conducted?
This trial has 16 study locations across California, Delaware, Georgia, Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.